315.00

2.26% 6.95

Bio Rad Laboratories Inc (BIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$308.05

Offen:

$309.74

24-Stunden-Volumen:

160.23K

Relative Volume:

0.76

Marktkapitalisierung:

$8.50B

Einnahmen:

$2.58B

Nettoeinkommen (Verlust:

$-778.69M

KGV:

-11.53

EPS:

-27.33

Netto-Cashflow:

$223.75M

1W Leistung:

-1.67%

1M Leistung:

+2.48%

6M Leistung:

+36.65%

1J Leistung:

-7.32%

1-Tages-Spanne:

$307.08

$316.20

1-Wochen-Bereich:

$307.08

$325.33

52-Wochen-Spanne:

$211.43

$373.69

Bio Rad Laboratories Inc Stock (BIO) Company Profile

Firmenname

Bio Rad Laboratories Inc

Sektor

Healthcare (1124)

Branche

Medical Devices (143)

Telefon

(510) 724-7000

Adresse

1000 ALFRED NOBEL DRIVE, HERCULES

Mitarbeiter

7,700

Twitter

@BioRadLifeSci

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

BIO's Discussions on Twitter

Vergleichen Sie BIO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BIO Bio Rad Laboratories Inc	315.00	8.31B	2.58B	-778.69M	223.75M	-27.33
ABT Abbott Laboratories	122.55	210.84B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	92.70	137.17B	19.35B	2.78B	3.82B	1.8696
SYK Stryker Corp	353.80	133.55B	24.38B	2.94B	4.07B	7.6159
MDT Medtronic Plc	100.77	127.71B	34.76B	4.79B	5.21B	3.7017
EW Edwards Lifesciences Corp	83.92	48.33B	5.88B	1.34B	799.60M	2.3489

Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-01	Hochstufung	Citigroup	Neutral → Buy
2024-08-28	Eingeleitet	Wells Fargo	Equal Weight
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-04-03	Herabstufung	Citigroup	Buy → Neutral
2023-12-07	Eingeleitet	UBS	Buy
2023-06-16	Eingeleitet	Wells Fargo	Overweight
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-01-28	Bestätigt	Citigroup	Buy
2020-01-08	Eingeleitet	Wells Fargo	Overweight
2020-01-07	Eingeleitet	Citigroup	Buy
2018-10-17	Eingeleitet	Goldman	Buy
2018-09-20	Eingeleitet	Morgan Stanley	Equal-Weight
2018-02-16	Herabstufung	CL King	Buy → Neutral
2017-07-13	Eingeleitet	Wells Fargo	Outperform
2017-06-28	Hochstufung	Deutsche Bank	Hold → Buy
2017-01-18	Eingeleitet	Deutsche Bank	Hold
2016-10-13	Eingeleitet	CL King	Buy
2015-05-06	Bestätigt	Jefferies	Buy
2009-12-18	Eingeleitet	Maxim Group	Buy
2009-11-06	Eingeleitet	Jefferies & Co	Buy
2009-07-17	Eingeleitet	Soleil	Buy
2007-09-26	Eingeleitet	Banc of America Sec	Buy
2007-02-23	Herabstufung	Robert W. Baird	Outperform → Neutral

Alle ansehen

Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten

Dec 09, 2025

Polymerase Chain Reaction (PCR) Market Rapid Growt 2025-2033: - openPR.com

Dec 09, 2025

Basic Statistics in Laboratory Quality Control - Labroots

Dec 09, 2025

Dec 07, 2025

Why (BIO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com

Dec 07, 2025

Dec 05, 2025

What is the fair value estimate for Bio Rad Laboratories Inc. (BUW) stock in 2025Market Sentiment Summary & High Conviction Buy Zone Picks - Newser

Dec 05, 2025

What insider purchases suggest about Bio Rad Laboratories Inc. Class stockEarnings Miss & Low Risk High Reward Ideas - Newser

Dec 05, 2025

How Bio Rad Laboratories Inc. (BUWA) stock performs in volatility spikesJuly 2025 Analyst Calls & Precise Buy Zone Tips - Newser

Dec 05, 2025

Why Bio Rad Laboratories Inc. (BUW) stock is upgraded to buyJuly 2025 EndofMonth & High Accuracy Swing Entry Alerts - Newser

Dec 05, 2025

Is Bio Rad Laboratories Inc. Class B stock a good hedge against inflationWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser

Dec 05, 2025

Dec 04, 2025

Why Bio Rad Laboratories Inc. (BUW) stock could break out in 2025Analyst Upgrade & Stock Market Timing Techniques - Newser

Dec 04, 2025

Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSys - pharmiweb.com

Dec 04, 2025

Will Bio Rad Laboratories Inc. (BUWA) stock recover faster than industryTrade Entry Summary & Long-Term Safe Return Strategies - Newser

Dec 04, 2025

Will Bio Rad Laboratories Inc. (BUW) stock deliver compounding returnsGap Down & Weekly Watchlist for Hot Stocks - Newser

Dec 04, 2025

Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSystems, Agilent Technologies, Abbott Labs, Bio-Rad Labs and MoreResearchAndMarkets.com - The AI Journal

Dec 04, 2025

Can Bio Rad Laboratories Inc. Class stock expand revenue streams2025 Year in Review & Weekly Top Gainers Alerts - Newser

Dec 04, 2025

How geopolitical risks impact Bio Rad Laboratories Inc. (BUWA) stockTrade Exit Report & Consistent Profit Trading Strategies - Newser

Dec 04, 2025

Why Bio Rad Laboratories Inc. stock is in analyst buy zoneEarnings Overview Summary & Low Risk High Reward Ideas - Newser

Dec 04, 2025

Will Bio Rad Laboratories Inc. (BUW) stock outperform energy sector in 2025Share Buyback & Free Weekly Watchlist of Top Performers - Newser

Dec 04, 2025

Why Bio Rad Laboratories Inc. (BUWA) stock is a must watch tickerEntry Point & Long-Term Capital Growth Strategies - Newser

Dec 04, 2025

Will Bio Rad Laboratories Inc. (BUW) stock recover faster than industry - Newser

Dec 04, 2025

Can Bio Rad Laboratories Inc. (BUWA) stock resist broad market declinesJuly 2025 Update & Weekly Stock Breakout Alerts - Newser

Dec 04, 2025

Fisher Asset Management LLC Sells 5,884 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat

Dec 03, 2025

Bio-Rad Laboratories (NYSE:BIO.B) Share Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat

Dec 03, 2025

Will Bio Rad Laboratories Inc. Class B stock announce special dividendNew Guidance & Verified Trade Idea Suggestions - Newser

Dec 03, 2025

What earnings margins imply for Bio Rad Laboratories Inc. Class B stockMarket Risk Report & Verified Technical Trade Signals - Newser

Dec 03, 2025

Dec 02, 2025

Bio-Rad Laboratories (NYSE: BIO) insider files to sell 776 shares under Rule 144 - Stock Titan

Dec 02, 2025